塔尔苏斯制药
TARS
68.07
-2.92
-4.11%
塔尔苏斯制药
US · TARS
#2389 按市值排名
上市于 2020
68.07
-2.92
-4.11%
实时 - 追踪5344个代码 - 心跳于8秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了2.0个百分点。
机构持股
- 机构持股比例
- 111.44% -2.04pp
- 机构数量
- 315
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund58.89%
Hedge Fund27.09%
VC/PE Fund11.05%
Public Company10.00%
Private Company3.25%
Individual/Insider3.06%
Government Pension Fund0.82%
Insurance Company0.29%
主要股东 截至 2026-06-30
BlackRock
8.79% · 3.86M 股
Deep Track Capital, LP
8.36% · 3.67M 股
RTW Investments, LP
7.65% · 3.36M 股
Janus Henderson Group plc
6.40% · 2.81M 股
Paradigm Biocapital Advisors LP
6.33% · 2.78M 股
Vanguard Capital Management, LLC
4.74% · 2.08M 股
Morgan Stanley
3.99% · 1.75M 股
Jennison Associates LLC
3.79% · 1.66M 股
Tang Capital Management, LLC
3.57% · 1.57M 股
Millennium Management LLC
3.25% · 1.43M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 26次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Bobak Azamian | Chairperson & CEO | 1.96% |
| William Link | Independent Director | 0.22% |
| Seshadri Neervannan | Chief Operating Officer | 0.18% |
| Bryan Wahl | General Counsel | 0.15% |
| Aziz Mottiwala | Chief Commercial Officer | 0.14% |
| Jeffrey S. Farrow | CFO & Chief Strategy Officer | 0.13% |
| Dianne Whitfield | Chief Human Resources Officer | 0.08% |
| Andrew Goldberg | Independent Director | 0.04% |
| Wendy Yarno | Lead Independent Director | 0.04% |
| Elizabeth Yeu-Lin | Chief Medical Advisor & Director | 0.04% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | William Link | Independent Director | Automatic Disposition | -12,299 | $78.33–80.01 |
| 2026-09-14 | William Link | Independent Director | Derivative Exercise and Sale | -201 | $78.33 |
| 2026-09-14 | David E. Pyott | Independent Director | Derivative Exercise and Retained | +201 | -- |
| 2026-09-14 | Wendy Yarno | Lead Independent Director | Derivative Exercise and Retained | +302 | -- |
| 2026-09-03 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $90.27–91.27 |
| 2026-09-03 | Seshadri Neervannan | Chief Operating Officer | Open Market Disposition | -4,564 | $85.00 |
| 2026-09-03 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Automatic Disposition | -13,953 | $85.00–90.00 |
| 2026-09-01 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $80.06 |
| 2026-09-01 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -8,000 | $81.80 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Automatic Disposition | -11,578 | $73.86–80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -5,387 | $80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -1,590 | $80.00 |
| 2026-08-31 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -77,698 | $73.96 |
| 2026-08-31 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -4,601 | $73.86 |
| 2026-08-24 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -81,332 | $71.85 |
| 2026-08-18 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -53,043 | $72.00 |
| 2026-06-24 | William Link | Independent Director | Other Derivative Acquisition | +3,223 | -- |
| 2026-06-24 | William Link | Independent Director | Other Derivative Acquisition | +3,837 | $64.34 |
| 2026-06-24 | David E. Pyott | Independent Director | Other Derivative Acquisition | +3,223 | -- |
| 2026-06-24 | David E. Pyott | Independent Director | Other Derivative Acquisition | +3,837 | $64.34 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
塔尔苏斯制药 讨论区 0 条评论